#USA #San Francisco #Securities Fraud #PROCEPT BioRobotics #Aquablation Therapy

PROCEPT BioRobotics Faces Securities Fraud Allegations

Overview

On August 10, 2026, Hagens Berman Sobol Shapiro LLP warned investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) regarding a securities class action lawsuit. This lawsuit arises from undisclosed inventory problems and hefty price dips in the company’s stock, raising concerns among the investors about the transparency of PROCEPT’s sales practices.

Background

The lawsuit’s scrutiny centers on the revelations that PROCEPT’s sales reports, particularly for their single-use handpiece—integral to their Aquablation therapy for enlarged prostates—were significantly misrepresented. Investors must be aware that the legal action targets claims from individuals who invested in PROCEPT stock from February 28, 2024, until February 25, 2026.

The firm Hagens Berman highlights that the investors may have been misled, as the company appeared to promote its sales growth without disclosing the full scope of sales manipulations. During this period, PROCEPT engaged in bulk order discount strategies that likely overstated their sales figures and revenue figures by encouraging customers to stockpile more handpieces than required.

Key Details of the Complaint

Part of the legal action points to a series of miscommunications surrounding the company's sales activities. Specifically:

• - Sales Underperformance: PROCEPT's decision to push bulk discounts prompted an imbalance between procedure demand and sales volume, skewing sales data over multiple quarters.
• - Investor Deceit: The complaint suggests that the executives may have intentionally obscured the truth regarding sales shortfalls. This deception became evident following several announcements of deteriorating sales figures.
• - Gradual Revelations: Beginning on August 6, 2025, the company disclosed poor Q2 results, missing sales expectations significantly. Later revelations on November 4, 2025, persisted with disappointing sales figures and management acknowledged poor inventory management practices.
• - Cumulative Loss: Ultimately, by February 25, 2026, the cumulative decline in PROCEPT shares was noted at over $22, translating to a staggering drop of 48% since the last high point.

Next Steps for Investors

Investors who made substantial trades in PROCEPT stock during the specified period are advised to reach out to the attorneys handling the case for possible recourse. Reed Kathrein from Hagens Berman is overseeing this investigation and is gathering information from individuals who may have insights relating to the case. They emphasize the importance of hearing from anyone who suffered financial losses during this timeframe.

Conclusion

Investors must remain vigilant and cognizant of the unfolding developments regarding PROCEPT’s operations. The firm Hagens Berman continues to investigate the circumstances surrounding the alleged securities fraud. For affected investors, taking action sooner rather than later would be prudent as investigations progress.

To contact the firm or learn more, reach out via email or visit their official site. Those with pertinent internal insights about PROCEPT might also consider whistleblower options as part of their contribution to the ongoing investigation.